Matthias Cavassini
Overview
Explore the profile of Matthias Cavassini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
412
Citations
7495
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wrona A, Justice A, Tate J, Rentsch C, Gordon K, Kidwai-Khan F, et al.
Cannabis
. 2025 Feb;
8(1):177-190.
PMID: 39968492
Objective: While cannabis use is common among people with HIV (PWH), there have been few studies examining the association of use with health outcomes among PWH. We aimed to evaluate...
2.
Gauthiez E, Pallanza M, Cavassini M, Calmy A
Rev Med Suisse
. 2025 Jan;
21(900-1):85-89.
PMID: 39812295
The year 2024 saw many advances in HIV care, both in terms of treatment and prevention. The cure of a patient from Geneva made headlines and helped in understanding the...
3.
Ingle S, Trickey A, Lankina A, McGinnis K, Justice A, Cavassini M, et al.
Alcohol Clin Exp Res (Hoboken)
. 2025 Jan;
49(2):407-417.
PMID: 39779221
Background: Alcohol use is measured in diverse ways across settings. Harmonization of measures is necessary to assess effects of alcohol use in multi-cohort collaborations, such as studies of people with...
4.
Haas A, Kusejko K, Cavassini M, Gunthard H, Stockle M, Calmy A, et al.
J Acquir Immune Defic Syndr
. 2025 Jan;
98(5):491-500.
PMID: 39748160
Introduction: Little is known about the clinical status of persons with HIV who re-engage in care after an interruption. We evaluated the immunologic and clinical characteristics of individuals re-engaging in...
5.
Fischer E, Renaud A, Grivaz P, Di Liberto G, Ryvlin P, Cavassini M, et al.
Brain Commun
. 2024 Dec;
7(1):fcae399.
PMID: 39726816
Neurocognitive impairment (NCI) is present in around 40% of people with HIV and substantially affects everyday life, adherence to combined antiretroviral therapy (cART) and overall life expectancy. Suboptimal therapy regimen,...
6.
Thoueille P, Marzolini C, Guidi M, Cavassini M, Decosterd L
Clin Infect Dis
. 2024 Dec;
PMID: 39673169
No abstract available.
7.
Thoueille P, Saldanha S, Schaller F, Choong E, Veuve F, Munting A, et al.
Front Pharmacol
. 2024 Dec;
15:1437400.
PMID: 39619609
Background: The pharmacokinetics of long-acting rilpivirine has mostly been studied in clinical trials, which do not fully address the uncertainties that arise in routine clinical situations. Aims And Methods: Our...
8.
Ballif M, Braun D, Calmy A, Bernasconi E, Cavassini M, Tissot F, et al.
BMJ Open
. 2024 Nov;
14(11):e094912.
PMID: 39578038
Introduction: Anti-retroviral therapy (ART) simplification strategies are needed for treatment-experienced people with HIV (PWH) and multidrug-resistant viruses. These individuals are commonly treated with boosted ART regimens and are thereby at...
9.
Lanz C, Meier J, Stockle M, Furrer H, Calmy A, Cavassini M, et al.
Clin Infect Dis
. 2024 Nov;
PMID: 39570670
Background: Most individuals on combination antiretroviral therapy (ART) have HIV plasma viral loads below the limit of detection. However, episodes of low-level viremia (LLV) are observed in subsets of individuals,...
10.
Tepekule B, Jorimann L, Schenkel C, Opitz L, Tschumi J, Wolfensberger R, et al.
iScience
. 2024 Nov;
27(11):111228.
PMID: 39555417
In people with HIV-1 (PWH), (MTB) infection poses a significant threat. While active tuberculosis (TB) accelerates immunodeficiency, the interaction between MTB and HIV-1 during asymptomatic phases remains unclear. Analysis of...